Avicanna Inc. (AVCNF)
OTCQX OTCQX Primary Summary
AVCNF Chart
Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain
Multi-centre, blinded, randomized placebo-controlled investigator initiated study, to be led by Dr. Hance Clarke and conducted at University Health Network Multi-centre, blinded, randomized placebo-controlled investigator initiated study, to be led by Dr. Hance Clarke and conducted at University Health Network
Avicanna Reports Q1 2025 Results and First Profitable Quarter
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q1 2025 and the of the Company's milestone of achieving its first profitable quarter.
Avicanna Inc. (AVCNF) Q4 2024 Earnings Call Transcript
Avicanna Inc. (OTCQX:AVCNF) Q4 2024 Earnings Call April 22, 2025 8:30 AM ET Company Participants Aras Azadian - Chief Executive Officer Phil Cardella - Chief Financial Officer Conference Call Participants Barbara Hickson - Private Investor Mark Merritt - Private Investor David Gordon - Private Investor Aras Azadian So good morning, everyone. Thank you for joining our 2024 Earnings and Corporate Update.
Avicanna Inc. Dividends
Avicanna Inc. Earnings
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
Avicanna Inc. (AVCNF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Avicanna Inc. ever had a stock split?
Avicanna Inc. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Aras Azadian B.Econ, Mba CEO | OTCQX Exchange | - ISIN |
| Canada Country | 87 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Avicanna Inc. is a pioneering biopharmaceutical entity focused on the development, research, and commercialization of innovative cannabinoid-based products. Catering to both the consumer and medical spheres, as well as the pharmaceutical industry on a global scale, Avicanna is at the forefront of leveraging evidence-based approaches to harness the potential of cannabinoids. Since its inception in 2016, with headquarters situated in Toronto, Canada, Avicanna has established itself as a leader in the cannabinoid research field, offering a wide range of proprietary products designed to meet various medical, consumer, and pharmaceutical needs. Through rigorous scientific exploration and a commitment to advancing cannabinoid science, Avicanna aims to address unmet medical needs and improve the quality of life for individuals worldwide.
Products and Services
- RHO Phyto: This is Avicanna's line of medical cannabis formulations, which includes a variety of delivery mechanisms such as oral, sublingual, topical, and transdermal products. These offerings boast different ratios of cannabinoids, aimed at providing targeted relief and addressing specific medical conditions efficiently.
- Pharmaceutical Products: Avicanna is also dedicated to the development of indication-specific pharmaceutical products. Among these is Trunerox, an adjuvant treatment for seizures that occur with Lennox-Gastaut Syndrome and Dravet Syndrome, showcasing the company's commitment to tackling severe neurological disorders through innovative cannabinoid-based therapies.
- Active Pharmaceutical Ingredients (APIs): Under the Aureus Santa Marta brand, Avicanna offers a range of CBD, THC, and CBG ingredients. These APIs are integral for the development and manufacturing of various products across the food, cosmetic, medical, and pharmaceutical industries, highlighting Avicanna's versatility and broad impact.
- MyMedi.ca Platform: This medical cannabis care platform underscores Avicanna’s dedication to comprehensive patient support. Offering a wide array of products along with bilingual pharmacist-led support, MyMedi.ca serves veterans, educates the medical community, and facilitates the integration of cannabis into healthcare practices. It stands out for its specialized services and educational resources.
- Collaborations and Research: Avicanna’s commitment to innovation is further exhibited through its research and collaboration agreement with a leading European pharmaceutical company. This partnership focuses on assessing Avicanna’s proprietary SEDDS technology in conjunction with various drug delivery systems, paving the way for novel pharmaceutical applications and formulations.
Contact Information
